Following the recent evolution in therapeutic strategies for GH-secreting pituitary adenomas, determining optimal individualized patient management is now crucial.
Results:
In multivariate analysis, PSMT was significantly linked to:
. Early remission: 45.3% patients in remission with PSMT vs 26.1% without; 
Conclusion
At 3 months and at long-term evaluation, pre-treated and no pre-treated groups were comparable for the main confounding factors except for IGF-1 at diagnosis which was higher in patients with PSMT at both evaluations.
PSMT was more beneficial for patients with somatotroph adenoma larger than 15 mm: Group 1: Size<15 mm + No PSMT Group 2: Size<15 mm +PSMT Group 3: Size>15 mm + No PSMT Group 4: Size>15 mm+ PSMT In multivariate analysis, group 3 (Size>15 mm, No PSMT) had a significant lower remission rate than the 3 other groups (p<0.01).
Noteworthy, no patient with a more than 18 mm adenoma or a mean GH exceeding 35 ng/ml at diagnosis was cured by surgery without PSMT.
